Covalent fragment screening to inhibit the E3 ligase activity of bacterial NEL enzymes SspH1 and SspH2

As the global fight against antimicrobial resistance in bacteria becomes increasingly pressing, new tool compounds are needed to understand and identify novel therapeutic targets. Here, cysteine-directed fragment-based drug discovery is coupled with a high throughput chemistry direct-to-biology screening platform to target the catalytic cysteine of a family of bacterial effector proteins, the Novel E3 Ligases (NELs) from Salmonella and Shigella. These effector E3 ligases are particularly interesting as a potential drug target because they are injected into host cells during infection, have no human homologues and disrupt host immune response to infection. We successfully identify lead compounds against the SspH subfamily of NELs from Salmonella and show that these proteins are inhibited by compound treatment, representing an exciting starting point for development into specific and potent tool compounds.